Have a Little Fun!

Inflammatory Bowel Disease

In older patients with inflammatory bowel disease (IBD), tumor necrosis factor alpha antagonist (anti-TNF) therapy and vedolizumab (an integrin receptor antagonist) were found to be comparable with regard to both safety and effectiveness, according to a study published in Alimentary Pharmacology & Therapeutics.

The authors point out how, unlike other autoinflammatory conditions, “IBD has the benefit of effective and safe gut specific anti-integrin therapies which can provide a platform off of which combinations can be employed.”